Immix Biopharma, Inc. (IMMX)

US — Healthcare Sector
Peers: ZVSA  HEPA  AVRO  EFTR  CNSP  NAVB  SONN    FRLN  ENVB  CWBR  ELEV  OCEA 

Automate Your Wheel Strategy on IMMX

With Tiblio's Option Bot, you can configure your own wheel strategy including IMMX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IMMX
  • Rev/Share 0.0
  • Book/Share 0.323
  • PB 7.2445
  • Debt/Equity 0.1104
  • CurrentRatio 1.8028
  • ROIC -2.0475

 

  • MktCap 65232866.0
  • FreeCF/Share -0.4511
  • PFCF -4.8693
  • PE -3.3259
  • Debt/Assets 0.0532
  • DivYield 0
  • ROE -1.3002

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
IMMX
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone adds 10 sites since the Company's most recent update.

Read More
image for news Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

About Immix Biopharma, Inc. (IMMX)

  • IPO Date 2021-12-16
  • Website https://www.immixbio.com
  • Industry Biotechnology
  • CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
  • Employees 18

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.